Gonadorelin

Gonadorelin (GnRH) is a naturally occurring decapeptide that acts as a gonadotropin-releasing hormone agonist. Its core function is to stimulate the release of luteinizing hormone (LH) and follicle stimulating hormone (FSH). It has established clinical uses in treating infertility, menstrual cycle irregularities, and hypogonadism, and for diagnostic pituitary assessment. Active research is exploring its promise in managing breast and prostate cancers and potentially mitigating Alzheimer's disease.

Gonadorelin Structure

• Formula: C55H75N17O13
• Molecular Weight: 1182.29 g/mol
• Sequence: pyroGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2

Gonadorelin Effects

Gonadorelin Research and Breast Cancer Prevention

Research links high lifetime estrogen exposure to increased breast cancer risk. Gonadorelin is investigated as a primary prevention method, targeting the suppression of ovarian estrogen production in high-risk postmenopausal women. This is a safe and cost-effective strategy, with studies projecting a risk reduction of 60% (10 years) to 70% (15 years) [1]. Furthermore, by reducing estrogen at the source, gonadorelin could significantly extend the efficacy of traditional anti-estrogen medications [4], which often encounter drug resistance.

Gonadorelin a Breakthrough in Prostate Cancer

As the most hormone-sensitive cancer, prostate cancer is successfully treated by controlling hormones. The use of GnRH led to the concept of medical castration and the development of Combined Androgen Blockade therapy (CAB). CAB is highly effective, especially when combined with early detection, achieving a cure rate of 99% of all prostate cancer.

Gonadorelin May Reduce Dementia Risk

The hormone LH influences neurological function, specifically in the hippocampus [9]. Elevated LH levels are associated with amyloid-beta (Abeta) plaques, a marker of Alzheimer's [10]. Suppressing LH is therefore a key research area for reducing Abeta pathology [11]. The strategy is to reduce LH while preserving beneficial testosterone levels [12]. Research highlights that the analogue leuprolide offers decreased Alzheimer's risk compared to other gonadorelin-related therapies due to its mechanism of suppressing CAR effects [13]. Current investigations are also focusing on how gonadorelin analogues influence the tandem genetic interaction of APOE and MS4A4A in Alzheimer's disease [14].

Gonadorelin Research

Gonadorelin is a peptide of significant research interest, operating within the established framework of Gonadotropin-releasing hormone (GnRH) pathways. Research has already delivered a highly successful treatment strategy for prostate cancer and provides strong indications for breast cancer prevention and neurodegenerative conditions. Gonadorelin demonstrates minimal adverse effects in mice. Gonadorelin for human application remains restricted to educational and scientific exploration. Human consumption remains prohibited. Only licensed researchers may obtain Gonadorelin if they are accredited investigators.

Article Author

The referenced literature was researched, compiled, and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate from Case Western Reserve University School of Medicine.

Scientific Journal Author

Dr. Giorgio Secreto is a leading scientist at the IRCCS National Cancer Institute in Italy, specializing in androgens and breast cancer. His foundational work on GnRH's effect on ovarian androgen levels is referenced [1, 3]. He does not endorse or promote this compound, and no affiliation exists between Peptide Sciences and this researcher.

Referenced Citations

G. Secreto et al., "A novel approach to breast cancer prevention: reducing excessive ovarian androgen production in elderly women," Breast Cancer Res. Treat., vol. 158, no. 3, pp. 553–561, 2016. D. V. Spicer and M. C. Pike, "Sex steroids and breast cancer prevention," J. Natl. Cancer Inst. Monogr., no. 16, pp. 139–147, 1994. G. Secreto, P. Muti, M. Sant, E. Meneghini, and V. Krogh, "Medical ovariectomy in menopausal breast cancer patients with high testosterone levels: a further step toward tailored therapy," Endocr. Relat. Cancer, vol. 24, no. 11, pp. C21–C29, 2017. E. S. Volleard, A. P. van Beck, F. A. J. Verburg, A. Rozs, and J. A. Land, "Gonadotropin releasing hormone agonist treatment in premenopausal women with hyperandrogenism of ovarian origin," J. Clin. Endocrinol. Metab., vol. 96, no. 5, pp. 1197–1201, May 2011. F. Labrie, "Hormonal therapy of prostate cancer," Prog. Brain Res., vol. 182, pp. 321–341, 2010. F. Labrie, "GnRH agonists and the rapidly increasing use of combined androgen blockade in prostate cancer," Endocr. Relat. Cancer, vol. 21, no. 4, pp. R301–317, Aug. 2014. F. Labrie, "Combined blockade of testicular and locally made androgens in prostate cancer: a highly significant medical progress based upon intracrinology," J. Steroid Biochem. Mol. Biol., vol. 145, pp. 144–156, Jan. 2015. F. Labrie, "Keynote of endocrinology in the victory against prostate cancer," Bull. Cancer (Paris), vol. 93, no. 9, pp. 849–868, Sep. 2006. V. Burnham, C. Sundby, A. Laman-Maharg, and J. Thornton, "Luteinizing hormone acts at the hippocampus to dampen spatial memory," Horm. Behav., vol. 89, pp. 55–63, 2017. C. V. Rao, "Involvement of Luteinizing Hormone in Alzheimer Disease Development in Elderly Women," Reprod. Sci. Thousand Oaks Calif, vol. 24, no. 3, pp. 355–368, 2017. J. Lin et al., "Genetic ablation of luteinizing hormone receptor improves the amyloid pathology in a mouse model of Alzheimer disease," J. Neuropathol. Exp. Neurol., vol. 69, no. 3, pp. 253–261, Mar. 2010. R. L. Bowen, T. Butler, and C. S. Atwood, "Nad All Androgen Deprivation Therapies Are Created Equal: Leuprolide and the Decreased Risk of Developing Alzheimer's Disease," J. Clin. Oncol., vol. 34, no. 23, p. 2800, Aug. 2016. M. A. Smith, P. L. Bowen, R. O. Nguyen, G. Perry, C. S. Atwood, and A. A. Rimm, "Putative Gonadorelin Releasing Hormone Against Therapy and Dementia: An Application of Medicare Hospitalization Claims Data to PLA JAD, vol. 63, no. 4, pp. 1259–1277, 2018. A. Clelems, J. E. Vargas, and J. R. Gonzalez, "APOE and MS4A4A interact with GnRH signaling in Alzheimer's disease: Disrupting in mab and Alzheimer Dement. J. Alzheimers Assoc., vol. 13, no. 4, pp. 493–497, Apr. 2017.